MedTrace Logo

A Study Investigating the Effects of Niagen™ in Healthy Adults.

NCT02712593 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 140

Last updated 2018-04-11

No results posted yet for this study

Summary

This study will evaluate the effect of repeated doses of Niagen™ on Niagen™ metabolite concentrations in blood, urine and muscle. There will be 3 doses of Niagen™ compared to a placebo. One quarter of subjects will receive the low dose of Niagen™, one quarter will receive the moderate dose of Niagen™, one quarter will receive the higher dose of Niagen™ and one quarter will reveive the placebo.

Conditions

  • Bioavailability

Interventions

DIETARY_SUPPLEMENT

Niagen™ 100

DIETARY_SUPPLEMENT

Niagen™ 300

DIETARY_SUPPLEMENT

Niagen™ 1000

OTHER

Placebo

Sponsors & Collaborators

  • ChromaDex, Inc.

    collaborator INDUSTRY

  • KGK Science Inc.

    lead INDUSTRY

Principal Investigators

  • Gordon Schacter, MD · KGK Science Inc.

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-03-21
Primary Completion
2017-03-17
Completion
2017-04-30

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02712593 on ClinicalTrials.gov